Joyce (@joyfelicio) posted a TikTok about tirzepatide (marketed as Mounjaro for diabetes, Zepbound for weight loss) that's racked up over 200,000 views. The Portuguese hashtags suggest she's promoting it for weight loss ("emagrecimento"). Without seeing the specific claims in her video, we can fact-check what the research actually shows about this GLP-1/GIP dual agonist.
What does tirzepatide actually do for weight loss?
Tirzepatide delivers some of the most impressive weight loss results we've seen in clinical trials. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) found that people taking the highest 15mg dose lost an average of 20.9% of their body weight over 72 weeks.
That's not a typo. We're talking about results that rival bariatric surgery in some cases. The 10mg dose led to 19.5% weight loss, and even the 5mg dose produced 16.0% weight loss. Compare that to semaglutide's 14.9% in STEP 1, and you can see why there's so much buzz.
The drug works by mimicking two hormones: GLP-1 and GIP. Both slow gastric emptying and reduce appetite, but the dual mechanism appears more effective than GLP-1 agonists alone.
Are these results typical for real-world users?
Clinical trials use carefully selected participants who get regular monitoring and support. Real-world results often differ, usually for the worse. But early data suggests tirzepatide's effectiveness translates reasonably well to clinical practice.
A 2023 study from Epic Research tracking over 18,000 patients found average weight loss of 15.2% at one year with tirzepatide versus 8.3% with semaglutide. That's still substantial, though lower than the trial results.
The catch? About 20-30% of people don't respond well to any GLP-1 medication. If you're not seeing meaningful weight loss (defined as 5% or more) after 12-16 weeks at therapeutic doses, it's probably not going to work for you.
What side effects should people know about?
Gastrointestinal issues dominate the side effect profile. In SURMOUNT-1, 81% of participants reported nausea, 51% had diarrhea, and 48% experienced vomiting. Most of these were mild to moderate and decreased over time.
The more serious concerns include potential thyroid tumors (seen in animal studies), pancreatitis, and gallbladder problems. The FDA requires a black box warning about thyroid C-cell tumors, though no human cases have been definitively linked to tirzepatide.
Starting doses begin at 2.5mg weekly and increase gradually to minimize side effects. The escalation schedule matters. People who jump to higher doses too quickly often can't tolerate the medication.
What's the deal with cost and access?
Here's where social media often glosses over reality. Tirzepatide costs around $1,000-1,200 per month without insurance. Zepbound (the weight loss formulation) has limited insurance coverage compared to Mounjaro for diabetes.
Many people turn to compounded versions or online pharmacies, which raises quality and safety questions. The FDA has warned about counterfeit semaglutide and tirzepatide products containing different ingredients than advertised.
Weight typically returns when you stop taking these medications. The SURMOUNT-4 trial showed people regained about two-thirds of their lost weight within a year of discontinuation.
What should you actually consider?
Tirzepatide represents a genuine breakthrough in obesity treatment, with weight loss results that were unthinkable from medication just a decade ago. The clinical trial data is solid, and real-world evidence looks promising.
But it's not magic. Success requires lifestyle changes, tolerance for side effects, and long-term financial commitment. The people in trials also received counseling on diet and exercise.
If you're considering tirzepatide, work with a healthcare provider who understands these medications. They can help determine if you're a good candidate and monitor for complications. Don't base major health decisions on TikTok videos, even well-intentioned ones.